FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Publications
  • Links
  • News
✕

Rare eye diseases: Eight million euros for research: Funding for four years

Claus Cursiefen

Claus Cursiefen

The European Union has supported a research proposal on new therapies to restore visual acuity in rare and severe ocular surface diseases under the Horizon Health program. The RESTORE VISION consortium, consisting of the Universities of Cologne, Galway, Milan, Linjöping and Paris, and four industrial partners, has received a total of eight million euros in funding over four years. The aim of this application is to establish new therapeutic options for seven rare, previously untreatable diseases of the ocular surface (aniridia, neurotrophic keratopathy, limbal stem cell insufficiency, scarring mucous membrane pemphigoid, EEC syndrome, corneal neovascularization, high-risk keratoplasty) by developing new drugs or repurposing existing drugs.
In collaboration with the Center for Clinical Studies (ZKS) Cologne, several pilot studies with patients are planned. The project leader from the Cologne side is Univ.-Prof. Dr. Claus Cursiefen, Director of the Center for Ophthalmology at the University Hospital of Cologne and the Faculty of Medicine: “Especially the European collaborative research and the possibility to conduct several first-in-men clinical trials at the Cologne site should enable a big step towards new therapies for rare, blinding eye diseases. We are especially pleased about the synergy with the existing DFG Research Group 2240.” The proposal was rated “very good” with 14 out of 15 points.

Related posts

April 23, 2025

SFB 1607 Launches Website and Celebrates TEO-C New Lab Location


Read more
April 23, 2025

New SFB 1607 Launched – Building on the Foundations of FOR2240


Read more

Fakultaetspreise 2024

February 27, 2024

Faculty prize for PD Dr. Schrittenlocher – Awarded for best habilitation in 2022


Read more

News

  • SFB 1607 Launches Website and Celebrates TEO-C New Lab Location
  • New SFB 1607 Launched – Building on the Foundations of FOR2240
  • Faculty prize for PD Dr. Schrittenlocher – Awarded for best habilitation in 2022
  • DOG poster award for Dr. Martina Maaß
  • Young Cologne Eye Researcher Šejla Gegić won Margarete Kramer Prize

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Claudia Bock
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
claudia.bock@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck
      Um unsere Website für Sie optimal zu gestalten und fortlaufend verbessern zu können, verwenden wir Cookies. Durch die weitere Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen zu Cookies und insb. der Möglichkeiten, der Verwendung von Cookies zu widersprechen, erhalten Sie in unserer Datenschutzerklärung.SchließenDatenschutzerklärung